Concord Biotech Limited

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 09:40:02 23/05/2024 BST			5-day change	1st Jan Change
1,454 ^INR	-0.39%		-0.26%	-1.18%

03-18	Concord Biotech Limited(BSE:543960) added to S&P Global BMI Index	CI
03-06	Concord Biotech's API Plant Gets GMP Certificate from Brazilian Health Regulator	MT

Concord Biotech Limited Announces Resignation of Anil Katyal as Independent Director

August 25, 2023 at 12:26 pm

Concord Biotech Limited informed that Mr. Anil Katyal Independent Director of the Company has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on August 25, 2023.

Latest news about Concord Biotech Limited

Concord Biotech Limited(BSE:543960) added to S&P Global BMI Index	03-17	CI
Concord Biotech's API Plant Gets GMP Certificate from Brazilian Health Regulator	03-06	MT
Concord Biotech Limited Receives Certificate from Brazilian Health Regulatory Agency	03-06	CI
India's Nifty 50 set to hit record high at open, surfing global rally	02-23	RE
Jefferies Adjusts Concord Biotech’s Price Target to INR1,410 From INR1,440, Keeps at Hold	02-12	MT
Certain Equity Shares of Concord Biotech Limited are subject to a Lock-Up Agreement Ending on 11-FEB-2024.	02-10	CI
Concord Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Jefferies Downgrades Concord Biotech to Hold From Buy, Adjusts Price Target to INR1,300 From INR1,260	11-10	MT
India's Cello World surges 29% on listing at $2.1 bln valuation	11-06	RE
Indian cookware maker Cello World's IPO garners strong response	11-01	RE
India's IRM Energy slides 11% in debut trade at over $200 million valuation	26/10/23	RE
India's JSW Infrastructure jump 20% in pre-open trading debut	03/10/23	RE
Concord Biotech Limited Announces Resignation of Utpal Hemendra Sheth as Independent Director	30/09/23	CI
India's JSW Infrastructure receives bids worth $7.3 billion in IPO	27/09/23	RE
Quadria Capital aims to raise up to $1 billion for new Asia healthcare fund	22/09/23	RE
Concord Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	06/09/23	CI
India's Aeroflex Industries soars over 81% in debut trade	31/08/23	RE
Concord Biotech Limited Announces Resignation of Anil Katyal as Independent Director	25/08/23	CI
US FDA Clears Concord Biotech's Manufacturing Plant in Gujarat, India	22/08/23	MT
Concord Biotech Limited Announces Cessation of Amit Varma as Non-Executive Non-Independent Director	19/08/23	CI
Concord Biotech Limited has completed an IPO in the amount of INR 15.505208 billion.	09/08/23	CI

Chart Concord Biotech Limited

Duration

Period

More charts

Company Profile

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.

Sector

Pharmaceuticals

Calendar

22/05/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,460 INR

Average target price

1,597 INR

Spread / Average Target

+9.36%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CONCORD BIOTECH LIMITED	-1.18%	1.83B
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.49B
BIOGEN INC.	-12.97%	32.79B
UCB	+63.62%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.52B
INCYTE CORPORATION	-7.31%	13.09B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.6B
SWEDISH ORPHAN BIOVITRUM AB	+5.32%	8.82B

Biopharmaceuticals